E C Borden
Overview
Explore the profile of E C Borden including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
220
Citations
3563
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kirkwood J, Strawderman M, Ernstoff M, Smith T, Borden E, Blum R
J Clin Oncol
. 2023 Jan;
41(3):425-435.
PMID: 36649675
Purpose: Interferon alfa-2b (IFN alpha-2b) exhibits antitumor activity in metastatic melanoma and on this basis has been evaluated as an adjuvant therapy following surgery for deep primary (T4) or regionally...
2.
Zhang K, Wong P, Zhang L, Jacobs B, Borden E, Aster J, et al.
Oncogene
. 2012 Jan;
31(43):4609-18.
PMID: 22249266
The Notch pathway is an evolutionary conserved signaling cascade that has an essential role in melanoblast and melanocyte stem cell homeostasis. Notch signaling is emerging as a key player in...
3.
Cheriyath V, Kuhns M, Jacobs B, Evangelista P, Elson P, Downs-Kelly E, et al.
Oncogene
. 2011 Oct;
31(17):2222-36.
PMID: 21996729
Hormonally regulated survival factors can have an important role in breast cancer. Here we elucidate G1P3, a survival protein induced by interferons (IFNs), as a target of estrogen signaling and...
4.
Cheriyath V, Kuhns M, Kalaycio M, Borden E
Br J Cancer
. 2011 Mar;
104(6):957-67.
PMID: 21364585
Background: Although inhibitors of histone deacetylase inhibitors (HDACis) in combination with genotoxins potentiate apoptosis, the role of proteases other than caspases in this process remained elusive. Therefore, we examined the...
5.
Bae S, Cheriyath V, Jacobs B, Reu F, Borden E
Oncogene
. 2007 Jul;
27(4):490-8.
PMID: 17653094
Human melanoma cell lines, SK-MEL-3 and SK-MEL-28, despite induction of the proapoptotic cytokine, Apo2L/TRAIL, did not undergo apoptosis in response to interferons (IFN-alpha2b or IFN-beta). Postulating that genes important for...
6.
Masci P, Olencki T, Wood L, Rybicki L, Jacobs B, Williams B, et al.
Clin Pharmacol Ther
. 2007 Mar;
81(3):354-61.
PMID: 17339865
Interferon-alpha1 (IFN-alpha1), which may have a primary role in innate immunity, differs significantly in amino-acid sequence from IFN-alpha2, the only recombinant IFN-alpha with substantial clinical evaluation. Patients with metastatic malignancies...
7.
Andersen J, Aaboe M, Borden E, Goloubeva O, Hassel B, Orntoft T
Br J Cancer
. 2006 Apr;
94(10):1465-71.
PMID: 16641915
Bladder cancer is among the most prevalent malignancies, and is characterised by frequent tumour recurrences and localised inflammation, which may promote tissue invasion and metastasis. Microarray analysis was used to...
8.
Chawla-Sarkar M, Bae S, Reu F, Jacobs B, Lindner D, Borden E
Cell Death Differ
. 2004 May;
11(8):915-23.
PMID: 15118763
Melanoma cells are relatively resistant to Apo2L/TRAIL (TNF-related apoptosis-inducing ligand). We postulated that resistance might result from higher expression of inhibitors of apoptosis including Bcl-2, FLIP (FLICE-like inhibitory protein) or...
9.
Chawla-Sarkar M, Lindner D, Liu Y, Williams B, Sen G, Silverman R, et al.
Apoptosis
. 2003 May;
8(3):237-49.
PMID: 12766484
IFNs are a family of cytokines with pleiotropic biological effects mediated by scores of responsive genes. IFNs were the first human proteins to be effective in cancer therapy and were...
10.
Smalley R, Weller E, Hawkins M, Oken M, Oconnell M, Borden E
Leukemia
. 2001 Jul;
15(7):1118-22.
PMID: 11455982
The Eastern Cooperative Oncology Group (ECOG) performed a prospectively randomized study (E6484) evaluating the use of interferon alfa 2a (IFN-alpha2a) in patients with aggressive low-grade or with intermediate-grade non-Hodgkin's lymphoma...